NASDAQ:PTCTPTC Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $49.90 +0.27 (+0.54 %) (As of 05/28/2020 04:00 PM ET) Add Compare Share Today's Range$49.53Now: $49.90▼$50.9950-Day Range$42.79MA: $48.51▼$53.8552-Week Range$30.79Now: $49.90▼$59.89Volume516,200 shsAverage Volume875,349 shsMarket Capitalization$3.14 billionP/E RatioN/ADividend YieldN/ABeta1.48 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. It has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.Read More Beat the Market (BTM) Rank™ 4.3 Analyst's Opinion Consensus RatingPTC Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.63, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $62.83, PTC Therapeutics has a potential upside of 25.9% from its current price of $49.90.Amount of Analyst CoveragePTC Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.5 Community Rank Outperform VotesPTC Therapeutics has received 498 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPTC Therapeutics has received 489 “underperform” votes. (Add your “underperform” vote.)Community SentimentPTC Therapeutics has received 50.46% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about PTC Therapeutics and other stocks. Vote “Outperform” if you believe PTCT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PTCT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPTC Therapeutics does not currently pay a dividend.Dividend GrowthPTC Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PTC Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,384,249.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of PTC Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PTC Therapeutics are expected to grow in the coming year, from ($4.56) to ($2.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PTC Therapeutics is -10.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PTC Therapeutics is -10.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPTC Therapeutics has a P/B Ratio of 5.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.49 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PTCT Previous Symbol CUSIPN/A CIK1070081 Webwww.ptcbio.com Phone908-222-7000Debt Debt-to-Equity Ratio0.56 Current Ratio3.18 Quick Ratio3.09Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$306.98 million Price / Sales10.22 Cash FlowN/A Price / Cash FlowN/A Book Value$8.41 per share Price / Book5.93Profitability EPS (Most Recent Fiscal Year)($3.45) Net Income$-251,580,000.00 Net Margins-90.83% Return on Equity-46.42% Return on Assets-17.31%Miscellaneous Employees511 Outstanding Shares62,875,000Market Cap$3.14 billion Next Earnings Date8/4/2020 (Estimated) OptionableOptionable NASDAQ:PTCT Rates by TradingView Receive PTCT News and Ratings via Email Sign-up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. PTC Therapeutics (NASDAQ:PTCT) Frequently Asked Questions How has PTC Therapeutics' stock been impacted by COVID-19 (Coronavirus)? PTC Therapeutics' stock was trading at $47.08 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PTCT stock has increased by 6.0% and is now trading at $49.90. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of PTC Therapeutics? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for PTC Therapeutics. When is PTC Therapeutics' next earnings date? PTC Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for PTC Therapeutics. How were PTC Therapeutics' earnings last quarter? PTC Therapeutics, Inc. (NASDAQ:PTCT) announced its earnings results on Thursday, April, 30th. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing the Zacks' consensus estimate of ($1.00) by $0.81. The biopharmaceutical company earned $68.30 million during the quarter, compared to analyst estimates of $81.90 million. PTC Therapeutics had a negative net margin of 90.83% and a negative return on equity of 46.42%. The business's revenue for the quarter was up 26.5% on a year-over-year basis. During the same period in the previous year, the business earned ($1.29) EPS. View PTC Therapeutics' earnings history. What price target have analysts set for PTCT? 8 analysts have issued 12 month price targets for PTC Therapeutics' shares. Their forecasts range from $45.00 to $85.00. On average, they expect PTC Therapeutics' share price to reach $62.83 in the next twelve months. This suggests a possible upside of 25.9% from the stock's current price. View analysts' price targets for PTC Therapeutics. Has PTC Therapeutics been receiving favorable news coverage? News coverage about PTCT stock has been trending very negative on Friday, according to InfoTrie. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. PTC Therapeutics earned a coverage optimism score of -3.2 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutPTC Therapeutics. Who are some of PTC Therapeutics' key competitors? Some companies that are related to PTC Therapeutics include Sarepta Therapeutics (SRPT), Catalent (CTLT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN), Dr.Reddy's Laboratories (RDY), Mylan (MYL), ACADIA Pharmaceuticals (ACAD), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Ascendis Pharma A/S (ASND), Jazz Pharmaceuticals (JAZZ), Bausch Health Companies (BHC), United Therapeutics (UTHR) and Myokardia (MYOK). View all competitors. What other stocks do shareholders of PTC Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals PLC- (GWPH), Bausch Health Companies (BHC), Regulus Therapeutics (RGLS), NVIDIA (NVDA), Cisco Systems (CSCO), Aduro BioTech (ADRO) and Gilead Sciences (GILD). Who are PTC Therapeutics' key executives? PTC Therapeutics' management team includes the following people: Dr. Stuart W. Peltz, Co-Founder, CEO & Exec. Director (Age 59)Dr. Allan Steven Jacobson, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 73)Ms. Christine Utter, Principal Financial Officer & Treasurer (Age 41)Mr. Marcio Souza, Chief Operating Officer (Age 40)Dr. Neil Almstead, Chief Technical Operations Officer (Age 52) What is PTC Therapeutics' stock symbol? PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT." Who are PTC Therapeutics' major shareholders? PTC Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (9.92%), Franklin Resources Inc. (8.78%), BlackRock Inc. (8.17%), State Street Corp (3.77%), Janus Henderson Group PLC (2.81%) and Alliancebernstein L.P. (2.55%). Company insiders that own PTC Therapeutics stock include Allan Steven Jacobson, Christine Marie Utter, Emily Luisa Hill, Marcio Souza, Mark Elliott Boulding, Michael Schmertzler, Neil Gregory Almstead and Stuart Walter Peltz. View institutional ownership trends for PTC Therapeutics. Which institutional investors are selling PTC Therapeutics stock? PTCT stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Bank of New York Mellon Corp, Federated Hermes Inc., Emerald Mutual Fund Advisers Trust, Pictet Asset Management Ltd., Emerald Advisers LLC, Morgan Stanley, and Morgan Stanley. Company insiders that have sold PTC Therapeutics company stock in the last year include Allan Steven Jacobson, Christine Marie Utter, Emily Luisa Hill, Marcio Souza, Mark Elliott Boulding, Neil Gregory Almstead, and Stuart Walter Peltz. View insider buying and selling activity for PTC Therapeutics. Which institutional investors are buying PTC Therapeutics stock? PTCT stock was acquired by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Alliancebernstein L.P., TimesSquare Capital Management LLC, Janus Henderson Group PLC, BlackRock Inc., Redwood Investments LLC, International Biotechnology Trust PLC, and Invesco Ltd.. View insider buying and selling activity for PTC Therapeutics. How do I buy shares of PTC Therapeutics? Shares of PTCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is PTC Therapeutics' stock price today? One share of PTCT stock can currently be purchased for approximately $49.90. How big of a company is PTC Therapeutics? PTC Therapeutics has a market capitalization of $3.14 billion and generates $306.98 million in revenue each year. The biopharmaceutical company earns $-251,580,000.00 in net income (profit) each year or ($3.45) on an earnings per share basis. PTC Therapeutics employs 511 workers across the globe. What is PTC Therapeutics' official website? The official website for PTC Therapeutics is www.ptcbio.com. How can I contact PTC Therapeutics? PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The biopharmaceutical company can be reached via phone at 908-222-7000 or via email at [email protected] This page was last updated on 5/29/2020 by MarketBeat.com Staff
